• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

    3/27/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email

    GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform.

    "Cranial procedures require an exceptional level of precision, planning, and real-time insight," said Michael Carter, Senior Vice President and President of Medtronic Cranial & Spinal Technologies. "With the Stealth AXiS™ surgical system, we are bringing together advanced navigation, robotics, and AI-enabled capabilities within the AiBLE™ smart ecosystem to support surgeons with deeper insights across the surgical workflow."

    A defining capability of the platform is its AI-enabled architecture, which supports advanced planning and visualization before, during, and after surgery. For cranial procedures, the system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps and visualize critical neural pathway associated with essential brain functions. The platform also integrates intraoperative ultrasound through GE HealthCare's bkActiv™, providing additional real-time imaging during procedures.

    "For complex brain surgeries, the more information you have, the better decisions you can make," said Dr. Michael Ivan, neurosurgeon at the University of Miami Health System. "Pre-operative planning with tools like tractography may help surgeons enhance surgical efficiency and support better patient outcomes." 1,2

    For ENT procedures, the Stealth AXiS™ surgical system delivers high-precision navigation and advanced visualization tailored to the intricate anatomy of the sinuses and skull base. Built around real-world ENT workflows, the system offers sharper anatomical detail and faster responsiveness to support confident decision-making in the OR, as well as intuitive, surgeon-centered workflows to create a familiar user experience while delivering enhanced capabilities.

    "Intraoperative navigation is critical in minimally invasive endoscopic surgery of the sinuses and skull base, helping surgeons confidently delineate complex anatomy within high-risk spaces," said Dr. Vijay Ramakrishnan, board-certified otolaryngologist and professor of Otolaryngology-Head & Neck Surgery at Indiana University School of Medicine. "The Stealth AXiS™ system leverages innovative technologies to enhance surgeon workflows and support procedural efficiency and confidence in the operating room."

    Additionally, the system's flexible architecture is designed to support continuous software innovation, expanded capabilities, and deeper ecosystem connectivity to help shape the next era of surgery.

    "The Stealth AXiS™ surgical system represents the next era of navigation for ENT surgery," said Sean Haag, President of the Ear, Nose, & Throat business at Medtronic. "Building on 25 years of navigation leadership, this system is designed to help surgeons move with greater clarity, confidence, and control in the OR, while creating a powerful platform for the next generation of ENT innovation."

    For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit www.medtronic.com/stealthaxis.

    About the Cranial & Spinal Technologies Business at Medtronic

    As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.

    About the Ear, Nose, & Throat Business at Medtronic

    Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have partnered with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX™ image-guided surgery system in 1998, we continue to advance the field with next-generation platforms including the Stealth AXiS™ Surgical System.

    About Medtronic

    Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

    Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

    For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

    Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

    Contacts:

    Christine Stewart

    Public Relations

    +1-269-377-2557

    Ingrid Goldberg

    Investor Relations

    +1-763-505-2696

    1Li Z, et al. World Neurosurgery. 2018;116:e291-e297.

     2 Guberman GI, et al. Neurology. 2025;105(9).

    (PRNewsfoto/Medtronic plc)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-for-cranial-and-ent-procedures-302727270.html

    SOURCE Medtronic plc

    Get the next $MDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    2/13/2026$116.00Overweight
    Barclays
    2/9/2026$121.00Hold → Buy
    Needham
    2/3/2026$117.00Buy
    Citigroup
    1/30/2026$114.00Overweight
    Wells Fargo
    1/6/2026Mkt Perform → Outperform
    William Blair
    11/19/2025$111.00Sell → Neutral
    Goldman
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    More analyst ratings

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

    GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform."Cranial procedures req

    3/27/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing

    Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a nove

    3/23/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

    $106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure acquisition proceeds$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients thro

    3/12/26 8:17:40 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Citigroup resumed coverage on Medtronic with a new price target

    Citigroup resumed coverage of Medtronic with a rating of Buy and set a new price target of $117.00

    2/3/26 6:56:06 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Medtronic Plc claimed ownership of 252,813,348 shares (SEC Form 3)

    3 - Medtronic plc (0001613103) (Reporting)

    3/5/26 8:39:25 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & Chief Financial Officer Pieton Thierry covered exercise/tax liability with 2,976 units of Ordinary Shares, decreasing direct ownership by 7% to 37,574 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    3/5/26 5:22:16 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & President Cardiovascular Kiil Harry Skip exercised 50,876 units of Ordinary Shares at a strike of $90.90 and sold $5,132,217 worth of Ordinary Shares (52,524 units at $97.71), decreasing direct ownership by 5% to 32,768 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    2/26/26 5:48:47 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.

    SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)

    3/27/26 10:30:11 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Medtronic plc (0001613103) (Filer)

    3/24/26 4:42:04 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Medtronic plc.

    10-Q - Medtronic plc (0001613103) (Filer)

    2/24/26 4:18:20 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for fourth quarter of fiscal year 2026

    GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte

    3/5/26 4:53:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for third quarter of fiscal year 2026

    GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

    12/4/25 4:32:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/15/23 3:34:14 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products